194 related articles for article (PubMed ID: 18379938)
1. Use of whole-body FDG PET-CT to aid in the diagnosis of occult sarcoidosis.
Tannen BL; Ghesani NV; Frohman L; Eichler JD; Maldjian PD; Chu DS
Ocul Immunol Inflamm; 2008; 16(1):25-7. PubMed ID: 18379938
[TBL] [Abstract][Full Text] [Related]
2. Whole-body 18FDG PET-CT imaging of systemic sarcoidosis: ophthalmic oncology and uveitis.
Shulman JP; Latkany P; Chin KJ; Finger PT
Ocul Immunol Inflamm; 2009; 17(2):95-100. PubMed ID: 19412870
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of unknown sarcoidosis associated to erythema nodosum with 18F-FDG PET/CT.
Rampin L; Musto A; Marzola MC; Tadayyon S; Ferretti A; Chondrogiannis S; Grassetto G; Rubello D
Rev Esp Med Nucl Imagen Mol; 2013; 32(3):190-2. PubMed ID: 23522858
[TBL] [Abstract][Full Text] [Related]
4. Fever of unknown origin: the role of 18F-FDG PET/CT.
Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
[TBL] [Abstract][Full Text] [Related]
5. Giant cell arteritis on 18F-FDG PET/CT.
Heston TF; Szabo Z
Clin Physiol Funct Imaging; 2009 Sep; 29(5):382-4. PubMed ID: 19522856
[TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
8. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
9. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
10. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
11. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
12. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
16. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature.
Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF
Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207
[TBL] [Abstract][Full Text] [Related]
17. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
Groheux D; Moretti JL; Baillet G; Espie M; Giacchetti S; Hindie E; Hennequin C; Vilcoq JR; Cuvier C; Toubert ME; Filmont JE; Sarandi F; Misset JL
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):695-704. PubMed ID: 18436392
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT findings of autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis.
Otsuka H; Morita N; Yamashita K; Nishitani H
Ann Nucl Med; 2007 Dec; 21(10):593-6. PubMed ID: 18092136
[TBL] [Abstract][Full Text] [Related]
19. F-18 FDG PET/CT detection of mediastinal malignancy in a patient with dermatomyositis.
Liau N; Ooi C; Reid C; Kirkwood ID; Bartholomeusz D
Clin Nucl Med; 2007 Apr; 32(4):304-5. PubMed ID: 17413581
[No Abstract] [Full Text] [Related]
20. FDG PET for gauging of sarcoid disease activity.
Adams H; Keijsers RG; Korenromp IH; Grutters JC
Semin Respir Crit Care Med; 2014 Jun; 35(3):352-61. PubMed ID: 25007087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
